{"filing":{"accession_number":"0001104659-26-070501","cik":"0001671502","ticker":"QNRX","company_name":"Quoin Pharmaceuticals, Ltd.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"tm2616916d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465926070501/tm2616916d1_8k.htm"},"events":[{"id":3327,"run_id":2911,"accession_number":"0001104659-26-070501","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Quoin announced that Japan's Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation to QRX003 lotion for the treatment of Netherton Syndrome. This regulatory milestone provides development incentives including prioritized consultation, reduced fees, tax benefits, priority review, and up to 10 years of market exclusivity, materially affecting the company's pipeline and competitive position.","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-06-04","items":[{"id":4248,"accession_number":"0001104659-26-070501","item_number":"7.01","item_title":"Regulation","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Quoin announced that Japan's MHLW granted Orphan Drug Designation to QRX003 lotion for Netherton Syndrome treatment. This is a material regulatory milestone for a biopharmaceutical company—orphan drug designation provides market exclusivity and development incentives—but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M\u0026A, impairment, or litigation). The disclosure warrants classification as a material regulatory/product development event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:52:02.102252+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4250,"accession_number":"0001104659-26-070501","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces Japan's MHLW Orphan Drug Designation for QRX003 lotion for Netherton Syndrome, which provides development incentives including prioritized consultation, reduced fees, tax benefits, priority review, and up to 10 years of market exclusivity. While this is a positive regulatory milestone that would materially affect investor assessment of the company's pipeline and competitive position, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation). This is a material regulatory achievement that warrants disclosure under \"other_material.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:52:02.102252+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4248,"accession_number":"0001104659-26-070501","item_number":"7.01","item_title":"Regulation","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Quoin announced that Japan's MHLW granted Orphan Drug Designation to QRX003 lotion for Netherton Syndrome treatment. This is a material regulatory milestone for a biopharmaceutical company—orphan drug designation provides market exclusivity and development incentives—but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M\u0026A, impairment, or litigation). The disclosure warrants classification as a material regulatory/product development event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:52:02.102252+00:00","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-06-04"},{"id":4250,"accession_number":"0001104659-26-070501","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces Japan's MHLW Orphan Drug Designation for QRX003 lotion for Netherton Syndrome, which provides development incentives including prioritized consultation, reduced fees, tax benefits, priority review, and up to 10 years of market exclusivity. While this is a positive regulatory milestone that would materially affect investor assessment of the company's pipeline and competitive position, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation). This is a material regulatory achievement that warrants disclosure under \"other_material.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:52:02.102252+00:00","company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","filing_date":"2026-06-04"}]}